Abstract: Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.
Type:
Grant
Filed:
December 1, 2021
Date of Patent:
May 7, 2024
Assignee:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Donald E. Ingber, Magdalena Kasendra, Alexandra Sontheimer-Phelps, Alessio Tovaglieri
Abstract: The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.
Type:
Grant
Filed:
February 28, 2018
Date of Patent:
April 23, 2024
Assignees:
UNIVERSITÉ DE LORRAINE, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE NANCY
Abstract: Provided are methods for repairing a wound or inducing the proliferative phase of a wound comprising administering a composition comprising a protease mixture comprising collagenases and a neutral protease to the wound in an amount effective for repair of wound tissue or for inducing the proliferative phase in the wound.
Abstract: There is provided a method of treating hay for preventing and/or reducing heat damage in high moisture hay and as well to preserve the same, the method including adding to hay a hay preservative including a hay preserving and heat reducing effective amount of at least one enzyme having a chitinase activity, either alone or in combination with a hay preserving and heat reducing effective amount of a yeast of the genus Pichia or a bacteria of the genus Pediococcus. There is also provided a method of treating hay for preventing and/or reducing heat damage in high moisture hay and as well to preserve the same, the method including adding to hay a hay preservative including a hay preserving and heat reducing effective amount of yeast of the genus Pichia.
Abstract: This present invention relates to compositions and methods of microbial enhanced oil recovery using Bacillus subtilis strains. The invention also relates to compositions and methods for performing oil degradation with Bacillus subtilis strains. The compositions and methods of the present invention are also used for enhanced commercial biosurfactant and enzyme production.
Type:
Grant
Filed:
February 17, 2020
Date of Patent:
February 6, 2024
Assignee:
Locus Solutions IPCo, LLC
Inventors:
Sean Farmer, Xiaozhou Zhang, Sharmistha Mazumder, Maja Milovanovic
Abstract: The invention relates to biomarkers in children's skin, in particular in the skin of infants, the expression of which changes when the skin is dry. Such markers are particularly advantageous in that they allow the skin's response to dehydration to be monitored. The inventors have developed methods for evaluating the in vitro efficacy of formulations in preventing the effects of dehydration on children's skin, using a skin model specifically capable of reproducing the characteristics of children's skin.
Abstract: A staining composition for staining cells and for use in a method of staining cells, a method of diagnosing mitotic activity and a method of diagnosing cancer. The composition comprises dried petunia petals at least partially dissolved in distilled water; and 400 milligrams of picric acid per gram of dried petunia petals. The method of staining cells includes rinsing a sample containing the cells with 10% of phosphotungistic acid or 10% of phosphomolybdic acid; staining the sample with the composition and dehydrating the samples with 100% Ethanol or Isopropanol. The method of diagnosing mitotic activity includes observing stained regions in the sample to identify mitotic activity indicated by stained regions. The method for diagnosing cancer includes quantifying mitotic figures in the sample which are identified by stained regions of the sample.
Abstract: An object of the present invention is to prepare a functional intestinal organoid from pluripotent stem cells. An intestinal organoid is prepared from pluripotent stem cells, by the following steps (1) to (4): (1) differentiating pluripotent stem cells into endoderm-like cells; (2) differentiating the endoderm-like cells obtained in step (1) into intestinal stem cell-like cells; (3) culturing the intestinal stem cell-like cells obtained in step (2) to form spheroids; and (4) differentiating the spheroids formed in step (3) to form an intestinal organoid, the step including culture in the presence of a MEK1/2 inhibitor, a DNA methylation inhibitor, a TGF-? receptor inhibitor, and a ?-secretase inhibitor, in addition to an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.
Type:
Grant
Filed:
May 2, 2018
Date of Patent:
January 2, 2024
Assignee:
PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY
Abstract: An ex-vivo lung solution for machine perfusion of donor lungs on OCS. The solution may be mixed with whole blood or packed red blood cells to form the OCS lung perfusion solution.
Type:
Grant
Filed:
July 20, 2022
Date of Patent:
January 2, 2024
Assignee:
TRANSMEDICS, INC.
Inventors:
Waleed H. Hassanein, Ihab Abdel Fattah, Paul Lezberg, Tamer I. Khayal, Robert Havener, Anas Abdelazim
Abstract: A composition and methods of using the composition for the control of mollusks are provided, which include an effective amount of one or more isolated Phasmarhabditis nematodes, wherein at least one of the isolated nematodes is P. californica, P. papillosa or P. hermaphrodita, and wherein the P. hermaphrodita does not comprise Moraxella osloensis.
Type:
Grant
Filed:
August 28, 2020
Date of Patent:
November 28, 2023
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Irma Tandingan De Ley, Rory McDonnell, Timothy Paine
Abstract: The purpose of the present invention is to provide a cardiac cell culture material which specifically acts on cardiac cells. In addition, another purpose of the present invention is to provide artificial organ material obtained by culturing by using said cardiac cell culture material, and a method for producing the same. Thus, provided is a cardiac cell culture, wherein functional cardiac tissue is favorably built by using a cardiac cell culture material containing VCAM-1.
Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells based on their released TGF-9 levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-9 levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.
Abstract: The present invention provides a sufficiently effective medicine for treatment and/or prevention of ischemic diseases, without performing isolation of therapeutic cells or removal of deleterious cells from blood cells/hemocytes. The blood cells and/or the hemocytes are subjected to the action of a saccharide. The saccharide is a monosaccharide, a disaccharide, a trisaccharide, a polysaccharides, or a copolymer containing a monosaccharide, a disaccharide, or a trisaccharide as a component. The saccharide is a copolymer of sucrose and epichlorohydrin.
Type:
Grant
Filed:
March 18, 2016
Date of Patent:
September 5, 2023
Assignee:
Foundation for Biomedical Research and Innovation at Kobe
Abstract: The invention provides an isolated thermostable polypeptide possessing FGF2 activity and having at least 85% sequence identity to SEQ ID NO: 2 (FGF2 wt) or a functional fragment thereof, and comprising at least one amino acid substitution R31L and the use thereof in the cell biology research, regenerative medicine and related medical applications or cosmetics. Further it discloses a culture medium comprising subjected FGF2 suitable for culturing a human pluripotent stem cells involving both human embryonic stem cells and induced pluripotent stem cells.
Type:
Grant
Filed:
October 3, 2016
Date of Patent:
September 5, 2023
Assignees:
Masarykova Univerzita, Enantis s.r.o.
Inventors:
Petr Dvorak, Pavel Krejci, Lukas Balek, Livia Eiselleova, Zaneta Konecna, Pavel Dvorak, David Bednar, Jan Brezovsky, Eva Sebestova, Radka Chaloupkova, Veronika Stepankova, Pavel Vanacek, Zbynek Prokop, Jiri Damborsky, Michaela Bosakova
Abstract: The present disclosure relates to a Bacillus amyloliquefaciens CJ14-6 strain isolated from traditional meju, a preparation method for soybean koji using the same, and a soybean koji prepared by the preparation method. The preparation method for soybean koji includes: soaking soybeans in water or adding waster to soybeans and steaming the soaked soybeans; and inoculating a Bacillus amyloliquefaciens CJ14-6 strain into the steamed soybeans, fermenting the steamed soybeans, and drying the fermented soybeans to prepare a soybean koji.
Type:
Grant
Filed:
April 8, 2020
Date of Patent:
July 18, 2023
Assignee:
CJ Cheiljedang Corporation
Inventors:
Hye Jin Kim, Dong Joo Shin, Hye Won Shin, Eun Seok Jang, Dae Ik Kang, Byoung Seok Moon, Seon Mi Oh, Sun A Cho
Abstract: A method to increase the efficiency of myotube generation and maturation from pluripotent stem cells comprising: (a) differentiating pluripotent stem cells to myogenic progenitors; and (b) terminally differentiating said myogenic progenitors from (a) into myotubes in the presence of at least one gamma secretase inhibitor, wherein myotube generation is increased in the presence of at least one gamma secretase inhibitor, as compared to differentiation in the absence of gamma secretase inhibitors.
Abstract: A method for sterilising a platelet lysate in the liquid state comprising at least the endogenous growth factors TGF-beta 1, EGF, PDGF-AB, IGF-1, VEGF and bFGF. The method comprising freezing the liquid platelet lysate in order to obtain a frozen platelet lysate, and irradiating the frozen platelet lysate with ionising radiation in order to obtain a sterilised platelet lysate, the irradiation being adapted so as to preserve at least 80% of the concentration of at least one of the endogenous growth factors chosen from the group consisting of TGF-beta 1, EGF, PDGF-AB, IGF-1 and VEGF.
Type:
Grant
Filed:
February 19, 2021
Date of Patent:
July 4, 2023
Assignee:
Maco Pharma
Inventors:
Bruno Delorme, Sabrina Viau, Francis Goudaliez
Abstract: This disclosure relates to methods of producing induced pluripotent (iPS), multipotent, and/or lineage-committed stem cells from differentiated cells, maintaining iPS, multipotent, and/or lineage-committed cells in culture, and re-differentiating the iPS and multipotent stem cells into any desired lineage-committed cell type.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
July 4, 2023
Assignee:
The USA, as represented by, the Secretary, Department of Health and Human Services
Inventors:
David D. Roberts, Sukhbir Kaur, Jeffrey S. Isenberg
Abstract: Described herein are methods, systems and apparatus for separating components of a biological sample; as well as methods of using compositions prepared by same.
Type:
Grant
Filed:
April 15, 2022
Date of Patent:
May 23, 2023
Inventors:
Sanjay Batra, Elizabeth G. Cellucci, Justin Joseph Batra, Jaya Krishna Rose Batra